Sarah A. Weiss
Rutgers, The State University of New Jersey(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immune Cell Function and Interaction
Most-Cited Works
- → Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors(2018)567 cited
- → Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations(2018)355 cited
- → Immunotherapy of Melanoma: Facts and Hopes(2019)280 cited
- → Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial(2018)276 cited
- → Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease(2019)190 cited
- → Impaired consciousness in patients with absence seizures investigated by functional MRI, EEG, and behavioural measures: a cross-sectional study(2016)116 cited
- → On the Interaction of Self-Regulation, Interoception and Pain Perception(2014)107 cited
- → A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1(2021)92 cited
- → Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma(2015)86 cited
- → Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma(2020)84 cited